DRD1 rs4532 polymorphism: A potential pharmacogenomic marker for treatment response to antipsychotic drugs

作者：Ota Vanessa Kiyomi; Spindola Leticia Nery; Gadelha Ary; dos Santos Filho Airton Ferreira; Santoro Marcos Leite; Christofolini Denise Maria; Bellucco Fernanda Teixeira; Ribeiro dos Santos Andrea Kely; Santos Sidney; Mari Jair de Jesus; Melaragno Maria Isabel; Bressan Rodrigo Affonseca; Cardoso Smith Marilia de Arruda; Belangero Sintia Iole^*

来源：Schizophrenia Research, 2012, 142(1-3): 206-208.

DOI：10.1016/j.schres.2012.08.003

• Schizophrenia
• DRD1
• Pharmacogenomics
• Treatment-resistant
• Antipsycotic
• Dopamine

We investigated the association of dopamine receptor D1 gene (DRD1) rs4532 polymorphism with antipsychotic treatment response in schizophrenia. We have analyzed 124 patients with schizophrenia, consisting of 59 treatment resistant (TR) and 65 non-TR. We found an association between G-allele and TR schizophrenia (p=0.001; adjusted OR=2.71). Setting the common AA-genotype as reference, the GG-homozygous presented a five-fold risk compared to AA-homozygous (p=0.010; OR=5.56) with an intermediate result for AG-genotype (p=0.030; adjusted OR=2.64). The DRD1 rs4532 polymorphism showed a dose-response gradient with increased risk for treatment resistance and may be a potential pharmacogenetic marker for antipsychotic drug treatment response.

• 出版日期2012-12